Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-150
Closed -$68 1527
2025
Q2
$68 Hold
150
﹤0.01% 1431
2025
Q1
$62 Buy
+150
New +$96 ﹤0.01% 1435
2024
Q4
Sell
-500
Closed -$425 1511
2024
Q3
$425 Hold
500
﹤0.01% 1368
2024
Q2
$334 Hold
500
﹤0.01% 1380
2024
Q1
$650 Hold
500
﹤0.01% 1339
2023
Q4
$287 Hold
500
﹤0.01% 1362
2023
Q3
$377 Hold
500
﹤0.01% 1341
2023
Q2
$365 Hold
500
﹤0.01% 1216
2023
Q1
$379 Hold
500
﹤0.01% 1253
2022
Q4
$480 Hold
500
﹤0.01% 1229
2022
Q3
$1K Hold
500
﹤0.01% 1282
2022
Q2
$2K Hold
500
﹤0.01% 1247
2022
Q1
$3K Hold
500
﹤0.01% 1226
2021
Q4
$3K Hold
500
﹤0.01% 1183
2021
Q3
$4K Hold
500
﹤0.01% 1145
2021
Q2
$4K Hold
500
﹤0.01% 1109
2021
Q1
$3K Hold
500
﹤0.01% 1073
2020
Q4
$3K Hold
500
﹤0.01% 1031
2020
Q3
$3K Buy
500
+200
+67% +$1.78K ﹤0.01% 1011
2020
Q2
$3K Hold
300
﹤0.01% 991
2020
Q1
$0 Buy
+300
New +$382 ﹤0.01% 1220

Other funds holding VXRT

Central Trust Company's VXRT Position: Q3 2025 in Review

Central Trust Company sold out of Vaxart (VXRT) in Q3 2025, closing a stake of 150 shares — an estimated $68 sold.

Central Trust Company first reported a position in VXRT in Q1 2020 and held it in 21 quarters. The position peaked at $4K in Q3 2021. 17 funds tracked by Wall St. Rank hold VXRT as of Q3 2025.

  • Central Trust Company reported no remaining Vaxart position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 150 Vaxart shares in Q3 2025, an estimated $68.
  • Central Trust Company first reported a position in Vaxart in Q1 2020 and held it in 21 quarters.
  • Central Trust Company's Vaxart position peaked at $4K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Vaxart as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.